A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC

Trial Profile

A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2016

At a glance

  • Drugs Technetium Tc99m etarfolatide (Primary) ; Vintafolide (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Diagnostic use; Therapeutic Use
  • Acronyms TARGET-NSCLC
  • Sponsors Endocyte
  • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
    • 07 Sep 2015 According to an Endocyte media release, final overall survival analysis from this trial were presented at the IASLC World Conference on Lung Cancer.
    • 07 Sep 2015 Results published in an Endocyte media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top